Stelios Kympouropoulos | MEP
European Parliament

Stelios Kympouropoulos, MEP, European Parliament

Stelios Kympouropoulos  Greek psychiatrist and politician of the New Democracy party who has been serving as a Member of the European Parliament since the 2019 elections.
He was born on July 9, 1985 in Athens. At the age of 14 months he was diagnosed with spinal muscular atrophy. At the age of 15 his case became the occasion to change the law on flag bearers in school parades. In 2003 he was admitted to the Department of Medicine of the National and Kapodistrian University of Athens, from where he received his degree in Medicine in 2010, with honors. In 2014 he received a master's degree in "Mental Health Promotion - Prevention of Psychiatric Disorders". In 2016, he received the Degree in Psychiatry and since then he worked until June 2019 as Curator B 'at the 2nd University Psychiatric Clinic of the University General Hospital "Attikon". In 2013, he pioneered the organization of the first Greek delegation to the pan-European event "Freedom Drive", which became the springboard for the creation of the first Independent Living Organization of Greece, "I-Living!", Which is an urban non-profit company run exclusively by individuals with a disability. On February 20, 2019, in the European elections he was elected MEP. He joined the EPP Group. He is a member of the EMPL Committee, PETI Committee, of the Delegation for relations with the Mashreq countries and of the Delegation to the Parliamentary Assembly of the Union for the Mediterranean. In addition, he is the EPP coordinator in COVI Committee; and a substitute member of the ENVI Committee; Vice Coordinator in SANT Committee; REGI Committee and the Subcommittee on Human Rights. He is also the co-chair of the Disability Intergroup of the European Parliament.


Day 1 - Wednesday 23 October @ 08:40

Opening keynote address: How will the current OMP amendments effect orphan drug development and patient access?

-How should industry respond in order to keep innovating more therapies for rare diseases?

-How will the pharmaceutical legislation affect R&D in rare diseases, regulation, affordability and accessibility to patients?

-How should each multi-s-takeholder interpret and act upon the proposal and changes in order to gain a more sustainable ecosystem?

-How can we boost research and development to tackle rare diseases and develop orphan medicines?

Day 2 - Thursday 24 October @ 09:35

Keynote panel: How much weight does the patient voice carry when it comes to influencing clinical trials, policy and orphan drug approvals?

- Are the current policy and regulatory frameworks in the EU helping or hindering patient access to medicines?

- How can clinicians and healthcare professionals help in developing clinical trials and regulatory pathways?

- How has the way we develop orphan drugs evolved over time (from policy, technology to engagement) with patients?

last published: 04/Jul/24 16:55 GMT

back to speakers